(Q35827907)

English

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

scientific article published in December 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Sujata Vaidyanathan

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Joanne Jermany

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Chingming Yeh

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Marie-Noelle Bizot

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Riccardo Camisasca

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

1 December 2006

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

62

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

690-698

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Renin inhibition: what are the therapeutic opportunities?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

A review and assessment of potential sources of ethnic differences in drug responsiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Molecular basis of ethnic differences in drug disposition and response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

The renin-angiotensin-aldosterone system: a specific target for hypertension management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20.881) on normal and adrenalectomized rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Inhibition of renin secretion by angiotensin. II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

Compliance and compliance-improving strategies in hypertension: the Japanese experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

27 July 2018

The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02696.X

21 January 2018

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02696.X

21 January 2018

Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02696.X

21 January 2018

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02696.X

21 January 2018

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02696.X

21 January 2018

Review: Potential of renin inhibition in cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885182

24 September 2018

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17118124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma renin activity could be a useful predictor of left ventricular hypertrophy in essential hypertensives

1 reference

https://pubmed.ncbi.nlm.nih.gov/17118124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17118124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of 24-h blood pressure control

1 reference

https://pubmed.ncbi.nlm.nih.gov/17118124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2006.02696.X

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35827907&oldid=2180831895"